Johnson Matthey delivers on upgraded guidance as Cormetech deal steals the spotlight

Johnson Matthey PLC's (LSE:JMAT) full-year results were broadly in line with the upgraded guidance the FTSE 100 specialty chemicals group had already provided, leaving the shares flat in early trading as investors focused instead on the $460 million Cormetech acquisition announced alongside the numbers. Panmure Liberum, which rates the stock a 'buy' with a 2310p target price, described the financial year to March 2027 as set to be "an exciting year" for the group.